Lupin Limited has informed to the exchanges that the USFDA inspected Lupin’s Somerset, New Jersey, U.S.A. manufacturing facility from January 2, 2023 to January 13, 2023.
According to the filing, the inspection closed with issuance of a Form-483 with two observations.
‘We are addressing the observations comprehensively and will work with the U.S. FDA to resolve these issues at the earliest’, the company said in a statement.
It further added, ‘We uphold quality and compliance with utmost importance and are committed to be compliant with CGMP standards across all our facilities.’
On Monday early morning trade, Lupin was trading at Rs750 per share lower by 0.74% on the BSE.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
